Charles Olson - SurModics Sr. VP and General Manager of Medical Device
| SRDX Stock | | | USD 35.63 0.40 1.11% |
SVP
Mr. Charles W. Olson is Senior Vice President Commercial and Business Development, Medical Devices of SurModics Inc. He joined the Company in July 2001 as Market Development Manager, was promoted in December 2002 to Director, Business Development, named General Manager of the Hydrophilic Technologies business unit in April 2004, and promoted to Vice President and General Manager, Hydrophilic Technologies in October 2004. In April 2005, the position of Vice President, Sales was added to his responsibilities. In November 2008, Mr. Olson was named Vice President of our Cardiovascular business unit, in October 2010, he was named Senior Vice President and General Manager, Medical Device, and in August 2016 he was named Senior Vice President of Commercial and Business Development, Medical Devices. Prior to joining Surmodics, Mr. Olson was employed as General Manager at Minnesota Extrusion from 1998 to 2001 and at Lake Region Manufacturing in project management and technical sales from 1993 to 1998 since 2016.
| Age | 61 |
| Tenure | 9 years |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
Olson received a B.S. degree in Marketing from Winona State University in 1987.
SurModics Management Efficiency
The company has return on total asset
(ROA) of
(0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.1696) %, meaning that it created substantial loss on money invested by shareholders. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to rise to -0.11 in 2025.
Return On Capital Employed is likely to rise to -0.04 in 2025. At this time, SurModics'
Other Current Assets are fairly stable compared to the past year.
Other Assets is likely to rise to about 6.7
M in 2025, whereas
Total Assets are likely to drop slightly above 142.8
M in 2025.
SurModics currently holds 33.24
M in liabilities with Debt to Equity
(D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. SurModics has a current ratio of 2.0, which is within standard range for the sector. Note, when we think about SurModics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Surmodics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 389 people. SurModics (SRDX) is traded on NASDAQ Exchange in USA. It is located in 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 and employs 389 people. SurModics is listed under Health Care Equipment & Supplies category by Fama And French industry classification.
Management Performance
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Suiter, Director Development | |
| Timothy Arens, VP of Corporate Devel. and Strategy | |
| Charles Olson, Sr. VP and General Manager of Medical Device | |
| Gary Maharaj, CEO and President and Director | |
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | |
| Gordon JD, General Legal | |
| Gordon Weber, General Legal | |
| Teryl Sides, Senior Interventions | |
| John Manders, Corporate Controller and Principal Accounting Officer | |
| Gregg Sutton, Vice President - Research & Development | |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to
measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to
predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.